首页 | 本学科首页   官方微博 | 高级检索  
     

文迪雅联合欣复衡治疗糖尿病肾病的临床观察
引用本文:Hou Q,Ao X,Li G,Zhang Y. 文迪雅联合欣复衡治疗糖尿病肾病的临床观察[J]. 中南大学学报(医学版), 2012, 37(1): 73-77. DOI: 10.3969/j.issn.1672-7347.2012.01.013
作者姓名:Hou Q  Ao X  Li G  Zhang Y
作者单位:1. 中南大学湘雅医院营养科, 长沙 410008;
2. 中南大学湘雅医院肾内科, 长沙 410008;
3. 中南大学湘雅医院内分泌科, 长沙 410008
基金项目:湖南省卫生厅资助项目(B2006-215)。
摘    要:目的:观察欣复衡(葛根素)片联合文迪雅(马来酸罗格列酮)对糖尿病肾病的治疗作用及其机制。方法:将确诊为糖尿病肾病的180例患者随机分为对照组(A组)58例,常规控制血糖及血压;治疗组(B组)60例,常规控制血糖及血压的基础上,单用口服文迪雅4 mg (每日1次);联合治疗组(C组)62例,常规控制血糖及血压并给予欣复衡片250 mg/次(每日3次),加用口服文迪雅4 mg(每日1次);均以12周为1个疗程,观察3组治疗前后的尿素氮、血肌苷,甘油三脂、胆固醇、低密度脂蛋白、高密度脂蛋白、平均动脉压、空腹血糖、餐后2 h血糖、糖化血红蛋白、24 h尿蛋白排泄率等指标的变化。结果:A组患者治疗前后各指标差异无统计学意义(P>0.05); B,C组患者治疗后与治疗前24 h尿蛋白排泄率、尿素氮、血肌苷均下降,差异有统计学意义(P<0.05),且以联合治疗组(C组)下降更为显著(P<0.05); B,C组患者治疗后与治疗前平均动脉压、空腹血糖、餐后2 h血糖、糖化血红蛋白均下降,差异有统计学意义(P<0.05),且以联合治疗组(C组)下降更为显著(P<0.05); B, C组患者治疗后与治疗前相比,甘油三脂、胆固醇、低密度脂蛋白均下降,高密度脂蛋白升高,差异有统计学意义(P<0.05),且以联合治疗组(C组)更为显著(P<0.05)。结论:文迪雅有较好的调节血脂代谢,降低尿蛋白排泄率的作用。欣复衡加用文迪雅治疗糖尿病肾病可改善肾功能及胰岛素的疗效,比单用文迪雅好,两者合用有协同作用。

关 键 词:文迪雅  葛根素  2型糖尿病  糖尿病肾病  临床观察  
收稿时间:2010-07-05

Puerarin combined with avandia for diabetic nephropathy
Hou Qian,Ao Xiang,Li Guo,Zhang Ying. Puerarin combined with avandia for diabetic nephropathy[J]. Journal of Central South University. Medical sciences, 2012, 37(1): 73-77. DOI: 10.3969/j.issn.1672-7347.2012.01.013
Authors:Hou Qian  Ao Xiang  Li Guo  Zhang Ying
Affiliation:1. Department of Nutrition, Xiangya Hospital, Central South University, Changsha 410008, China;
2. Department of Nephrology, Xiangya Hospital, Central South University, Changsha 410008, China;
3. Department of Endocrinology, Xiangya Hospital, Central South University, Changsha 410008, China
Abstract:Objective: To observe the effect and mechanism of avandia and puerarin used in combination for diabetic nephropathy. Methods: A total of 180 patients with diabetic nephropathy were randomly divided into 3 groups. The control group (58 patients, group A) were treated with routine therapy including controling the blood glucose and blood pressure, while 60 patients in group B were treated by avandia besides routine treatment of the control group. Anoter 62 cases in group C were administed with puerarin combined with avandia for 12 weeks. The indexes such as urea nitrogen, serum creatinine, triglyceride, cholesterol, low density lipoprotein, high density lipoprotein, mean arterial pressure, fasting bloodglucose, 2h plasma glucose, glycosylated hemoglobin, and 24 h urinary albumin excretion rate were tested before and after the treatment. Results: No significant differences were found in the indexes such as triglyceride, serum cholesterol,low density lipoprotein, high density lipoprotein, glycosylated hemoglobin, malonaldehyde, erythrocuprein, blood urea nitrogen, serum creatinine and 24 h urinary albumin excretion rate among the 3 groups (P>0.05). There were no significant differences in all indexes before and after the treatment in group A (P>0.05). After the treatment, 24 h urinary albumin excretion, urea nitrogen, serum creatinine, mean arterial pressure, fasting blood glucose, 2 h plasma gluose, glycosylated hemoglobin, triglyceride, serum cholesterol, low density lipoprotein decreased significant (P<0.05) while high density lipoprotein increased significant (P<0.05). Conclusion: Avandia has better effect on adjusting the blood lipid and decreasing the urinary albumin excretion rate. Puerarin combined with avandia is more effective for improving the renal function and remission of islet function than using avandia alone. Puerarin and avandia have significant synergism.
Keywords:avandia  puerarin  type 2 diabetes mellitus  diabetic nephropathy  clinical research
本文献已被 CNKI 万方数据 PubMed 等数据库收录!
点击此处可从《中南大学学报(医学版)》浏览原始摘要信息
点击此处可从《中南大学学报(医学版)》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号